Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38865670.
- Also identified by DOI 10.1200/PO.24.00204 and PMC identifier 11653999.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors